



ASX ANNOUNCEMENT

4 April 2019

European Patent Issued to Cynata Therapeutics

Melbourne, Australia; 4 April 2019: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, announced today that the European Patent Office (EPO) has granted a patent covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology. The patent, entitled “Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions,” is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

The patent provides further intellectual property protection for the Cymerus technology, including CYP-001, a treatment being developed for steroid-resistant graft versus host disease (GvHD) and which is the subject of a license option agreement between Cynata and FUJIFILM.

Dr. Ross Macdonald, Cynata’s Chief Executive Officer:

“We are very pleased with this important development in our goal to continue to strengthen our robust intellectual property assets around Cymerus, our therapeutic stem cell platform technology.”

Mr. Junji Okada, FUJIFILM’s Director Corporate Vice President:

“This new patent is a significant advancement in the protection of the intellectual property around Cynata’s Cymerus technology. We look forward to working with Cynata to finalise the license agreement.”

The inventors named on the patent are Dr Gene Uenishi and Professor Igor Slukvin. Professor Slukvin is a founder, advisor and shareholder of Cynata.

The patent has an expiration date of 12 March 2034.

Ends

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Rosa Smith, Australia Media Contact, +61 (0) 475 305 047, rosa.smith@mcpartners.com.au
Annie Starr, U.S. Media Contact, +1 973.768.2170 , astarr@6degreespr.com

About Graft-versus-host-disease

Graft-versus-host-disease (GvHD) is a complication that can occur after a bone marrow transplant or similar procedure, when the donor’s immune cells (from the “graft”) attack the recipient of the transplant (the “host”). The only approved treatment for GvHD is corticosteroid therapy, which is typically only effective in about 50 percent of patients. When GvHD fails to improve or worsens despite steroid treatment, patients are described as having steroid-resistant GvHD. The prognosis for these patients is poor, with mortality rates in excess of 90 percent.¹

¹ Westin JR, Saliba RM, De Lima M, et al. Steroid-Refractory Acute GVHD: Predictors and Outcomes. *Adv Hematol.* 2011; 2011:601953.



About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale and without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.